Stryker reports index change, shares hold their ground on NYSE

By Julia Schmitt, Sector & Peer Group desk. Reviewed prior to publication on 2026-06-29, 12:48.

Stryker Corp. (US8636671013) has been removed from several Russell growth benchmarks while continuing to trade on the NYSE in the S&P 500 healthcare cohort. This index reshuffling comes as analysts keep relatively high price targets on the medical products group.

What the Russell move means

According to MarketScreener, Stryker has been dropped from the Russell 1000 Growth Benchmark as part of the latest reconstitution, with the stock last quoted at around 332.71 dollars. A related note flagged removal from the broader Russell 3000E Growth Benchmark, signaling a recalibration of its representation in style indices.

The Russell changes do not affect Stryker's core NYSE listing under the ticker SYK or its inclusion in the S&P 500, where it sits in the health care equipment segment. Index rebalancing can influence passive fund flows, but the fundamental business remains driven by orthopaedics and medtech demand.

How analysts view Stryker today

On the analyst side, Leerink Partners recently initiated coverage on Stryker with an Outperform rating and a price target of 407 dollars, underscoring confidence in earnings growth despite a mature valuation. Goldman Sachs maintains a Neutral stance but has adjusted its target to 363 dollars, pointing to robust operations but a full valuation relative to peers.

Across the wider coverage universe, the average target price sits near 386.80 dollars, implying upside from the latest cash quote. Stryker's market capitalization stands at roughly 128 billion dollars, putting it among the larger medtech names alongside peers such as Johnson & Johnson's MedTech division and Zimmer Biomet.

Recent product news in medtech

Beyond index and analyst dynamics, Stryker has maintained an active product pipeline. On June 2, the company announced the launch of the TPX HD small bone power tool, designed for demanding orthopaedic procedures including total joint revisions, minimally invasive surgery and oral maxillofacial operations. The system targets challenging cases where surgeons must cut metal in confined spaces while maintaining control.

Mike Carlin, president of Stryker's Ortho Tech division, highlighted that revision surgeries are among the most demanding procedures and require precise, reliable instruments. The TPX HD launch complements Stryker's broader orthopaedic portfolio, which spans joint replacement implants, surgical navigation and powered instruments used in operating rooms worldwide.

The business behind the stock

Stryker generates most of its revenue from orthopaedics, MedSurg, neurotechnology and spine, with products ranging from hip and knee implants to hospital beds and endoscopy equipment. Flagship lines include joint replacement systems and powered tools that support surgeons in reconstructive and trauma procedures, as well as patient-handling equipment for hospitals and clinics.

Where the shares trade today

The Stryker Corp. shares (US8636671013) trade on the NYSE under the ticker SYK at around 332.71 dollars as of the latest available close, with extended trading indications slightly higher.

This article is for informational purposes only and does not constitute investment advice, a recommendation or an offer to buy or sell any securities. All data are based on sources cited and may change over time.